Ajkunic, Azra
Sayar, Erolcan http://orcid.org/0000-0002-3922-5683
Roudier, Martine P.
Patel, Radhika A. http://orcid.org/0009-0008-4889-6818
Coleman, Ilsa M.
De Sarkar, Navonil http://orcid.org/0000-0003-2139-7951
Hanratty, Brian http://orcid.org/0000-0003-4580-649X
Adil, Mohamed
Zhao, Jimmy
Zaidi, Samir
True, Lawrence D.
Sperger, Jamie M.
Cheng, Heather H. http://orcid.org/0000-0002-1365-0702
Yu, Evan Y.
Montgomery, Robert B.
Hawley, Jessica E.
Ha, Gavin http://orcid.org/0000-0001-7578-7272
Persse, Thomas
Galipeau, Patricia
Lee, John K. http://orcid.org/0000-0002-6570-2180
Harmon, Stephanie A.
Corey, Eva http://orcid.org/0000-0002-9244-3807
Lang, Joshua M. http://orcid.org/0000-0002-0943-8872
Sawyers, Charles L.
Morrissey, Colm
Schweizer, Michael T.
Gulati, Roman
Nelson, Peter S.
Haffner, Michael C. http://orcid.org/0000-0003-0809-6425
Article History
Received: 12 December 2023
Accepted: 3 May 2024
First Online: 17 May 2024
Competing interests
: J. Zhao is currently an employee at Astra Zeneca. L.D. True is a co-founder and has equity in Alpenglow Biosciences. H.H. Cheng was a paid consultant to AstraZeneca in the past and has received research funding from Astellas, Clovis Oncology, Color Foundation, Janssen, Medivation, Promontory Therapeutics, Sanofi, and royalties from UpToDate. E.Y. Yu served as paid consultant/received honoraria Amgen, AstraZeneca, Bayer, Churchill, Dendreon, EMD Serono, Incyte, Janssen, Merck, Clovis, Pharmacyclics, QED, Seattle Genetics, and Tolmar and received research funding from Bayer, Daiichi-Sankyo, Dendreon, Merck, Taiho, and Seattle Genetics. R.B. Montgomery received research funding from AstraZeneca, ESSA, Ferring and Janssen Oncology. J.E. Hawley received consulting fees from ImmunityBio and research funding to her institution from Bristol Myers Squibb, Astra Zeneca, Vaccitech, Crescendo and Macrogenics. J. K. Lee has received research funding from Immunomedics and serves as a scientific advisor for and has equity in PromiCell Therapeutics. E. Corey received sponsored research funding from AbbVie, Astra Zeneca, Foghorn, Kronos, MacroGenics, Bayer Pharmaceuticals, Forma Pharmaceuticals, Janssen Research, Gilead, Arvina, and Zenith Epigenetics. J.M. Lang served as paid consultant/received honoraria from Sanofi, AstraZeneca, Gilead, Pfizer, Astellas, Seattle Genetics, Janssen, and Immunomedics. C.L. Sawyers serves on the board of directors of Novartis, is a co-founder of ORIC Pharmaceuticals, and is a co-inventor of enzalutamide and apalutamide. He is a science adviser to Arsenal, Beigene, Blueprint, Column Group, Foghorn, Housey Pharma, Nextech, KSQ, and PMV. M.T. Schweizer is a paid consultant/received honoraria from Sanofi, AstraZeneca, PharmaIn, and Resverlogix and has received research funding from Novartis, Zenith Epigenetics, Bristol Myers Squibb, Merck, Immunomedics, Janssen, AstraZeneca, Pfizer, Hoffman-La Roche, Tmunity, SignalOne Bio, Epigenetix, Xencor, Incyte and Ambrx, Inc. P.S. Nelson served as a paid advisor for Bristol Myers Squibb, Pfizer, and Janssen. M.C. Haffner served as a paid consultant/received honoraria from Pfizer and has received research funding from Merck, Novartis, Genentech, Promicell and Bristol Myers Squibb. All other authors declare no potential conflicts of interest.